Peter Blume-Jensen, Acrivon Therapeutics CEO (via YouTube)
October 19, 2022 09:14 AM EDTUpdated October 20, 02:27 PM
Financing
Deals

Can a lit­tle start­up equipped with an Eli Lil­ly castoff make it big with an on­col­o­gy IPO? In 2022?

John Carroll

Editor & Founder

The ex­ec­u­tive crew and back­ers at the lit­tle start­up Acrivon clear­ly aren’t averse to risk. They hand­ed over a mod­est $5 mil­lion in cash to …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

A service from the Financial Times